Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614133 | 0.83 | IKBKB (0.50) | GSK3BKDM4ECYP1A2CYP2C9IKBKB | |
| SCHEMBL15960083 | 0.81 | MAPT (0.51) | GSK3BKDM4ECYP1A2CYP2C9IKBKB | |
| Lithium Ion SCHEMBL30334419 | 0.79 | GSK3B (0.40) | GSK3BKDM4ECYP1A2CYP2C9IKBKB | |
| SCHEMBL15878596 | 0.77 | GSK3B (0.61) | GSK3BDAORXFP1PKMGPR35 | |
| SCHEMBL5493304 | 0.77 | IKBKB (0.40) | KDM4EGLACYP1A2CYP2C9IKBKB | |
| SCHEMBL102283 | 0.76 | KDM4E (0.53) | KDM4EGLACYP1A2CYP2C9IKBKB | |
| SCHEMBL1974281 | 0.76 | GSK3B (0.44) | GSK3BKDM4EGLADAORXFP1 | |
| SCHEMBL31223143 | 0.76 | GSK3B (0.44) | GSK3BKDM4EDAOMAPTRXFP1 | |
| SCHEMBL3229132 | 0.76 | GPR35 (0.45) | KDM4EDAOCYP1A2CYP2C9IKBKB | |
| SCHEMBL20894252 | 0.74 | GSK3B (0.42) | GSK3BDAORXFP1PKMGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987042-B1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014170403-A1 | KINASE INHIBITORS | UNIVERSITY OF TARTU (EE) | 2014-10-23 | — | — | WO | disclosed |
| US-8853208-B2 | Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
| CN-101384605-A | Novel aminoalcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
| CN-101316851-A | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | BRISTOL MYERS SQUIBB CO (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1987042-A2 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | sanofi-aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093365-A2 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | GSK3B 656/4885KDM4E 1319/4885GLA 4344/4885 |
| US-20090076002-A1 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | AADAT, PNMT, MCHR1 | GSK3B 3540/4885KDM4E 411/4885GLA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.